Biotech proved a surprisingly bright spot in 2022’s startup correction
No startup sector was entirely immune from the 2022’s market uncertainty — except maybe AI — but some proved more resilient than others. Biotech was one of the most fortunate. The sector recorded 1,054 U.S.-based deals in 2022, worth a collective $30.7 billion, according to Pitchbook data. Those figures fell short of the 1,415 biotech…